OPTUNEINFORMATION

Latest updates are in the scientific articles section.

Last updated: 4/27/2020

Click here to go to the "Official" Optune™ Website

High compliance with Optune™ linked to greatest survival benefit for glioblastoma
29% 5 year survival in high compliance group compared to 4.5% in control group.(Added 1/26/19)

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
Read this if you are going to use Optune™ - it will help prevent the most comon problems.

Results from the trial for newly diagnoes GBM:
5 year survival rate more than doubles the standard of care! (added 9/24/17)

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs. Temozolomide Alone for Glioblastoma
This may become the new standard of care for Glioblastoma multiforme. (added 12/15/15)

Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients
Optune can now be used even if you have a non programmable shunt

New data on how Tumor Treating Fields Works

The name of the treatment has been changed from Novocure TTF100-A to Optune™ on 11/14/2014


Optune™ is a unique new form of treatment for brain tumors: it uses Tumor Treating Fields (TTF) to kill dividing cells. These fields are delivered by removable transducer arrays that are placed on the head.

This was approved by the United States FDA in 2011 for use in patients with recurrent glioblastoma multiforme and in 2015 for use in patients with newly diagnosed glioblastoma multifore

Tumor Treating Fields have been added to the NCCN guidelines as the standard of care for treatment of recurrent glioblastom multiform. See http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf (free registration is required).

Click here for a news video about the Novocure NovoTTF-100A.


Click on the links below for more information on Optune™.